Locations:
SearchSGLT2 inhibitors already show heart benefits in diabetes patients
For patients with heart failure with preserved ejection fraction (HFpEF), current treatments address only accompanying conditions and symptoms. Therapy commonly involves treating high blood pressure and coronary artery disease, and encouraging weight loss and smoking cessation.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
However, in 2020 we may see FDA approval of a class of medications, SGLT2 inhibitors, for the treatment of HFpEF. These medications already have shown reduced risk of cardiovascular death and heart failure hospitalization in patients with type 2 diabetes. Research is ongoing — yet promising — in HFpEF patients without diabetes.
In this video, learn more about why SGLT2 inhibitors are one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Cleveland Clinic partners with Palantir to create logistical command center
A Q&A with organizational development researcher Gina Thoebes
Cleveland Clinic transformation leader led development of benchmarking tool with NAHQ
Raed Dweik, MD, on change management and the importance of communication
Small business owners expand their networks and gain new insights
Leadership pearls from Margaret McKenzie, MD, hospital vice president
Advice from four CNOs on how to embrace innovation and collaboration
Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items